Insmed Inc (INSM)vsTheravance Biopharma Inc (TBPH)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
TBPH
Theravance Biopharma Inc
$15.29
+2.62%
HEALTHCARE · Cap: $726.14M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 464% more annual revenue ($606.42M vs $107.46M). TBPH leads profitability with a 98.5% profit margin vs -2.1%. TBPH earns a higher WallStSmart Score of 63/100 (C+).
INSM
Hold39
out of 100
Grade: F
TBPH
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
-402.8%
Fair Value
$3.88
Current Price
$15.29
$11.41 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Every $100 of equity generates 45 in profit
Keeps 99 of every $100 in revenue as profit
Strong operational efficiency at 43.6%
Revenue surging 144.7% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Moderate valuation
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : TBPH
The strongest argument for TBPH centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 98.5% and operating margin at 43.6%. Revenue growth of 144.7% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : TBPH
The primary concerns for TBPH are P/E Ratio, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while TBPH is a growth play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
TBPH is growing revenue faster at 144.7% — sustainability is the question.
TBPH generates stronger free cash flow (-6M), providing more financial flexibility.
Bottom Line
TBPH scores higher overall (63/100 vs 39/100), backed by strong 98.5% margins and 144.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Theravance Biopharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?